[KDIGO guideline on the evaluation and management of candidates for kidney transplantation].
作者信息
Morath Christian, Zeier Martin
机构信息
Nierenzentrum Heidelberg, Zentrum für Innere Medizin, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 162, 69120 Heidelberg, Deutschland.
出版信息
Nephrologe. 2022;17(1):44-50. doi: 10.1007/s11560-021-00561-8. Epub 2022 Jan 7.
Abstract
摘要
相似文献
1
[KDIGO guideline on the evaluation and management of candidates for kidney transplantation].
Nephrologe. 2022;17(1):44-50. doi: 10.1007/s11560-021-00561-8. Epub 2022 Jan 7.
2
KDOQI US Commentary on the 2020 KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.
Am J Kidney Dis. 2021 Jun;77(6):833-856. doi: 10.1053/j.ajkd.2020.11.017. Epub 2021 Mar 18.
3
KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.
Transplantation. 2020 Apr;104(4S1 Suppl 1):S11-S103. doi: 10.1097/TP.0000000000003136.
4
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.
Am J Kidney Dis. 2020 Mar;75(3):299-316. doi: 10.1053/j.ajkd.2019.10.005. Epub 2020 Jan 29.
5
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.
Am J Kidney Dis. 2014 May;63(5):713-35. doi: 10.1053/j.ajkd.2014.01.416. Epub 2014 Mar 16.
6
KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.
Am J Kidney Dis. 2015 Mar;65(3):354-66. doi: 10.1053/j.ajkd.2014.10.005. Epub 2014 Nov 18.
7
KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C.
Am J Kidney Dis. 2020 May;75(5):665-683. doi: 10.1053/j.ajkd.2019.12.016. Epub 2020 Apr 9.
8
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
Am J Kidney Dis. 2010 May;55(5):773-99. doi: 10.1053/j.ajkd.2010.02.340. Epub 2010 Apr 3.
9
Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management.
Kidney Int. 2018 Oct;94(4):663-673. doi: 10.1016/j.kint.2018.06.011.
10
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Am J Kidney Dis. 2017 Dec;70(6):737-751. doi: 10.1053/j.ajkd.2017.07.019. Epub 2017 Sep 21.
引用本文的文献
1
[Malignant neoplasms and transplantation].
Inn Med (Heidelb). 2025 Sep;66(9):896-902. doi: 10.1007/s00108-025-01960-y. Epub 2025 Jul 29.
本文引用的文献
1
Long-Term Survival after Kidney Transplantation.
N Engl J Med. 2021 Aug 19;385(8):729-743. doi: 10.1056/NEJMra2014530.
2
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712.
3
Donor and transplant candidate selection for solid organ transplantation during the COVID-19 pandemic.
Am J Transplant. 2020 Nov;20(11):3113-3122. doi: 10.1111/ajt.16138. Epub 2020 Jul 15.
4
KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.
Transplantation. 2020 Apr;104(4S1 Suppl 1):S11-S103. doi: 10.1097/TP.0000000000003136.
5
Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.
Transplantation. 2020 Apr;104(4):708-714. doi: 10.1097/TP.0000000000003137.
6
Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease-A trial protocol for the CARSK study.
Am Heart J. 2019 Aug;214:175-183. doi: 10.1016/j.ahj.2019.05.008. Epub 2019 May 22.
7
KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.
Kidney Int Suppl (2011). 2018 Oct;8(3):91-165. doi: 10.1016/j.kisu.2018.06.001. Epub 2018 Sep 19.
8
Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.
Kidney Int. 2018 Mar;93(3):560-567. doi: 10.1016/j.kint.2017.10.024. Epub 2018 Jan 9.
9
Anti-phospholipase A₂ receptor antibodies in recurrent membranous nephropathy.
Am J Transplant. 2015 May;15(5):1349-59. doi: 10.1111/ajt.13133. Epub 2015 Mar 12.
10
Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy.
Transplantation. 2015 Aug;99(8):1709-14. doi: 10.1097/TP.0000000000000630.
Zotero 插件